Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04322617 | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer(ATHENA) | recruiting | Phase 2 / Phase 3 | 1,200 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05059951 | Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer(CREATE) | recruiting | — | 15,000 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 |
| clinicaltrials |
| NCT06440954 | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases(EPIC) | recruiting | Phase 2 | 220 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03979170 | Patient-derived Organoids of Lung Cancer to Test Drug Response | recruiting | — | 50 | University Hospital, GenevaOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05266846 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK(BEYOND) | recruiting | Phase 2 | 78 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05584267 | Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy | recruiting | Phase 2 | 140 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06109558 | The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC(PROFILE) | recruiting | Phase 1 / Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06256237 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | recruiting | Phase 2 | 30 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04865250 | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC(iReP) | recruiting | Phase 2 | 20 | University Hospital HeidelbergOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06418087 | Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)(DUPLE) | recruiting | Phase 2 | 49 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT05804786 | Prospective Cohort of Diagnostic Bronchoscopy for Peripheral Lung Lesions | recruiting | — | 1,240 | Seoul National University Bundang HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06109454 | Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery | recruiting | — | 240 | Liaoning Cancer Hospital & InstituteOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06383728 | Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma(GALAXY-02) | recruiting | Phase 2 | 51 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04680377 | Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients(Microdurva) | recruiting | — | 44 | Jun Zhang, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06403735 | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 250 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT06404164 | Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection | recruiting | N/A | 3,000 | Guangdong Provincial People's HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06399926 | Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir | recruiting | — | 64 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06300177 | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | recruiting | Phase 3 | 522 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06387017 | Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway(BIOCEPTION) | recruiting | N/A | 750 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06369181 | Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC | recruiting | — | 50 | Fudan UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06169956 | An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany(NENI) | recruiting | — | 400 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02889666 | A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer(CCODG-NSCLC) | recruiting | Phase 1 | 500 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial | recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06361784 | Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)(LM) | recruiting | — | 150 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05704920 | Integrating Artificial Intelligence Into Lung Cancer Screening.(DACAPO) | recruiting | N/A | 2,722 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06361589 | Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients | recruiting | — | 200 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06360627 | Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT | recruiting | N/A | 100 | University of ZurichOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06329908 | DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs | recruiting | Early Phase 1 | 20 | Zhen-Yu DingOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06327594 | Assessment System of Sarcopenia in Lung Cancer Patients | recruiting | — | 1,500 | West China HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04733430 | LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice(LALUCA) | recruiting | — | 500 | Karl Landsteiner Institute for Lung Research and Pneumological OncologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06225804 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 164 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT06020430 | Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06032052 | Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients | recruiting | Phase 2 | 49 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06037733 | Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | recruiting | Phase 3 | 686 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06053099 | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)(ROSIE) | recruiting | N/A | 300 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05085028 | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(REFINE-Lung) | recruiting | Phase 3 | 1,750 | Imperial College LondonOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06286150 | Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery | recruiting | N/A | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05332925 | Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC(TUMORIN) | recruiting | — | 25 | Jun Zhang, MD, PhDOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05377658 | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05965024 | Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer | recruiting | — | 377 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262386 | Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial | recruiting | N/A | 358 | Chang Gung Memorial HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2024source: clinicaltrials